EMA Reviewing Guide To Support New Genome Editing Technologies, CAR-T Cell Therapies
The European Medicines Agency is updating its five-year old guideline on drugs containing genetically modified cells to factor in rapid scientific developments in relation to gene editing technologies, and the development of promising new cancer immunotherapies, such as CAR-T cells.
You may also be interested in...
EMA’s Advanced Therapies Panel To Set Up Medtech Group
The 2020 work plan of the European Medicines Agency’s Committee on Advanced Therapies includes initiatives to support the implementation of the EU regulations on medical devices and IVDs.
EU Guides On ATMP Trials, Genetically Modified Cells To Be Finalized This Year
The 2020 work plan of the European Medicines Agency’s committee on advanced therapies shows that two keenly-awaited guidelines are due to be finalized this year.
CAR-T Cells Addressed In Updated EMA Guide On Drugs Containing Genetically-Modified Cells
The European Medicines Agency's current thinking on the clinical development of CAR-T cells is outlined in a new annex.